Results 11 to 20 of about 7,958,059 (273)

Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns [PDF]

Dermatology Practical & Conceptual
Introduction: IL-17 and IL-23 inhibitors have transformed the management of moderate-to-severe psoriasis and other inflammatory diseases through targeted immune modulation.
Ingyun Park, Ali Bayrouti, Duncan MacIntyre, Vivian Le, Khoa Nguyen   +4 more
doaj   +3 more sources

MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review [PDF]

Therapeutic Advances in Gastroenterology
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is more prevalent in patients with psoriasis compared to healthy individuals.
José González Fernández, Lucía Prieto-Torres, Mariano Ara Martín, Samuel J. Martínez-Domínguez   +3 more
doaj   +3 more sources

Off-label dermatologic uses of IL-23 inhibitors

Journal of Dermatological Treatment
Background While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels ...
Justin Porter, Lacey Zimmerman, Melissa Nickles, Sheryl Hoyer   +3 more
doaj   +3 more sources

Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits [PDF]

Dermatology Practical & Conceptual
Introduction: Psoriasis is a chronic inflammatory multisystem disease for which IL-17 and IL-23 inhibitors have transformed treatment. However, high costs, and the possibility of overtreatment in patients with excellent and sustained responses have ...
Edoardo Cammarata, Chiara Airoldi, Jacopo Colombo, Andrealuna Ucciero, Luca Mastorino, Veronica Arese, Lorenza Burzi, Franco Castelli, Massimo Chiarpenello, Francesca Graziola, Claudia Leporati, Michela Ortoncelli, Pella Paolo, Ginevra Pertusi, Alessia Pisterna, Pietro Quaglino, Simone Ribero, Gianluca Rossotto, Rossana Tiberio, Paolo Dapavo, Paola Savoia   +20 more
doaj   +2 more sources

Efficacy and safety of IL-23 inhibitors in the treatment of moderate to severe ulcerative colitis: a meta-analysis based on randomized controlled trials [PDF]

Frontiers in Medicine
BackgroundInterleukin-23 (IL-23) plays a central role in the pathogenesis of ulcerative colitis (UC) by promoting Th17-mediated intestinal inflammation. While monoclonal antibodies targeting the IL-23p19 subunit have shown promise in clinical trials, the
Minyang He, Huixian Liang, Xiangcheng Fan, Xiangcheng Fan, Leimin Sun, Leimin Sun   +5 more
doaj   +2 more sources

Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials [PDF]

Central European Journal of Immunology, 2023
Boyang Gao, Haojie Shentu, Suyong Sha, Dongying Wang, Xi Chen, Zhenwei Huang, Nan Dong, Haijia Lai, Jianying Xu, Xiaoshuai Zhou   +9 more
doaj   +2 more sources

Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis) [PDF]

Dermatology and Therapy
Introduction Psoriasis involving special or high-impact areas (scalp, nails, palms/soles, genitalia) is associated with a disproportionate functional and psychological burden that is often underestimated by conventional severity scores and remains ...
Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, Francesco Messina, Luca Mastorino, Nicole Macagno, Andrea Carugno, Marco Campoli, Maria Concetta Fargnoli, Viviana Lora, Agnese Rossi, Helena Gioacchini, Luca Potestio, Giovanni Marco D’Agostino, Martina Maurelli, Giampiero Girolomoni, Marco Romanelli, Valentina Dini, Francesco Loconsole, Francesca Satolli, Gianluca Pagnanelli, Claudia Lasagni, Andrea Michelerio, Martina Dragotto, Piergiorgio Malagoli, Nicola Zerbinati, Diego Orsini, Anna Campanati, Matteo Megna, Tommaso Bianchelli, for the Italian Landscape Group, Antonio Costanzo, Simone Ribero, Alessandra Narcisi   +33 more
doaj   +2 more sources

Comparative Role of Anti-TNF Agents versus IL-12/23 Inhibitors in Inflammatory Bowel Disease: An Updated Review [PDF]

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Treatments for Crohn's Disease (CD) and Ulcerative Colitis (UC), two conditions that fall under the umbrella of Inflammatory Bowel Disease (IBD), must be both safe and effective. This review compares the effectiveness and safety of anti-TNF agents and IL-
Xue Bin Leong, Chuan Zhe Tang, Chloe Zi Ying Lee, Zoe Ling Hui Lee, Thai Hau Koo   +4 more
doaj   +2 more sources

Impact of angiotensin converting enzyme inhibition on post- coronary artery bypass interleukin 6 release [PDF]

, 2002
Background: Angiotensin 1 converting enzyme (ACE) inhibitors reduce morbidity and mortality after coronary artery bypass graft surgery (CABG). This benefit may result from an anti- inflammatory action.
Humphries, S.E., Rumley, A., Lowe, G.D., Montgomery, H.E., Sanders, J., Brull, D.J.   +5 more
core   +8 more sources

The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice: A Register-Based Analysis.

Dermatology, 2023
BACKGROUND: Interleukin (IL) inhibitors have made completely cleared skin achievable for many patients with moderate to severe psoriasis in clinical trial settings. Few observational studies assess treatment response in accordance with treatment goals in
Norlin JM, Löfvendahl S, Schmitt-Egenolf M.   +2 more
europepmc   +2 more sources